State of the direct care workforce: Data & insight for Medicaid leaders and advocates
Challenges within the direct care workforce threaten the health and wellbeing of millions. Here’s a look at the...
NAMD Urges CMS to Mitigate State Costs on Controversial Alzheimer’s Drug
In formal comments, NAMD calls on Medicare to step up and cover the Alzheimer’s drug Aduhelm. Failure to do so would significantly increase costs for state Medicaid programs.
Author
- NAMD
Focus Areas
In a controversial decision, the Food and Drug Administration approved Aduhelm, a drug intended to treat Alzheimer’s disease. Now Medicare must decide if it will cover the drug, and its decision has significant cost implications for state Medicaid programs. If Medicare does not cover it and Medicaid becomes the primary source of coverage, NAMD estimates Medicaid spending for Aduhelm could increase by 250 percent or more.
Related resources
NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS's proposed rule on the Medicaid Drug Rebate Program (MDRP).
NAMD Submits Comments on Congressional Request for Information on Dually Eligible Members
NAMD highlights strategies to improve systems of care for dually eligible members.
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.